Tocilizumab in immune checkpoint inhibitor-induced myositis, myocarditis, and myasthenic syndrome: a rare case report and review of the literature
ARP Rheumatology · 2025-12-30 · 4 (4) · 300-304
DOI: 10.63032/rfpy6607 ↗At a glance
Fallbericht in ARP Rheumatology, published online on 2025-12-30. Written by Hugo Gonçalves and 9 co-authors. Institution: Rheumatology, Hospital de Braga. Major MEDLINE topics: Myocarditis, Immune Checkpoint Inhibitors, Myositis, Antibodies, Monoclonal, Humanized. Cited 4 times so far (Crossref).
Abstract (original language)
Immune-related adverse events (irAEs) associated with immune checkpoint inhibitors (ICI) are becoming more frequent with the growing use of these agents in routine clinical oncology. This mechanism enhances the anti-tumor immune response, increasing the risk of activating autoreactive T cells, and leading to immune-mediated manifestations. The spectrum of these manifestations is widely variable. ICI-associated myositis is among the most severe irAEs, being a rare but serious complication with significant morbidity and mortality, particularly when accompanied by myocarditis and/or myasthenic crisis, which can all occur concurrently and worsen clinical outcomes. We report the case of a 78-years-old man with metastatic colon adenocarcinoma who developed ICI-associated myositis with concomitant myocarditis and myasthenic syndrome. In the presented case, the use of tocilizumab, an anti-interleukin 6 (IL-6)-receptor monoclonal antibody, was effective in treating the myositis and myocarditis, but not the myasthenic component of this ICI-associated myositis.
Subjects
MeSH terms (MEDLINE)
Substances
Authors and institutions
- Rheumatology, Hospital de Braga.
- Unidade Local de Saúde da Guarda.
- Unidade Local de Saúde de Braga.
- Oncology, Hospital de Braga.
- Hospital de Braga.
Cite
APA
Gonçalves, H., Augusto, D., Pereira, P., Ferreira-Campinho, C., Correia, A. M., Ferreira, C., Costa, E., Silva, J. L., Ribeiro, A. R., & Almeida, D. E. (2025). Tocilizumab in immune checkpoint inhibitor-induced myositis, myocarditis, and myasthenic syndrome: a rare case report and review of the literature. ARP Rheumatology, 4(4), 300-304. https://doi.org/10.63032/rfpy6607
Vancouver
Gonçalves H, Augusto D, Pereira P, Ferreira-Campinho C, Correia AM, Ferreira C, et al. Tocilizumab in immune checkpoint inhibitor-induced myositis, myocarditis, and myasthenic syndrome: a rare case report and review of the literature. ARP Rheumatology. 2025;4(4):300-304. doi:10.63032/rfpy6607
BibTeX
@article{Gonalves2025,
author = {Gonçalves, Hugo and Augusto, Duarte and Pereira, Paulo and Ferreira-Campinho, Carla and Correia, Ana Margarida and Ferreira, Catarina and Costa, Emanuel and Silva, Joana Leite and Ribeiro, Ana Roxo and Almeida, Diogo Esperança},
title = {Tocilizumab in immune checkpoint inhibitor-induced myositis, myocarditis, and myasthenic syndrome: a rare case report and review of the literature},
journal = {ARP Rheumatology},
year = {2025},
volume = {4},
number = {4},
pages = {300--304},
doi = {10.63032/rfpy6607}
}
EUVIMED